LGC Clinical Diagnostics Launches Innovative Reference Material for NIPT Discordant Twin Applications

Gaithersburg, Maryland, USA - 21 September 2026 - LGC Clinical Diagnostics, a leader in quality solutions for molecular diagnostics, is delighted to announce the launch of the Seraseq® Discordant Twins - Matched cfDNA (T21 Female / Euploid Male) (Lyophilized) (Material Number: 0720-1188). This novel reference material expands the company's industry-leading non-invasive prenatal testing (NIPT) portfolio, providing clinical laboratories and in vitro diagnostics (IVD) developers with a critical tool to validate and monitor Next-Generation Sequencing (NGS) assays in complex multifetal pregnancy scenarios.
Non-invasive prenatal testing using cell-free DNA (cfDNA) has revolutionized prenatal screening. However, twin pregnancies, specifically discordant twin gestations where one fetus carries a chromosomal abnormality such as Trisomy 21 (Down syndrome) while the co-twin is euploid, present significant clinical and analytical challenges. Differences in individual fetal fraction, twin zygosity, and sex chromosome complement require highly sensitive and robust assay performance to avoid falsified or masked results.
The Seraseq® Discordant Twins - Matched cfDNA reference material directly addresses these workflow challenges. Formulated in a patient-like matrix, this full-process control combines matched cell-free DNA representing a Trisomy 21 female fetus alongside a male euploid co-twin. Offered in a stable, easy-to-ship lyophilized format, it offers laboratories an accessible and consistent benchmark to support method development, analytical validation, batch release, and routine quality assurance.
"Accurately assessing fetal fraction and detecting aneuploidies in multifetal gestations remains one of the most challenging areas in reproductive genetics," said Catherine Huang, Senior Director of R&D and Custom Business, QMT at LGC Clinical Diagnostics. "By providing a true-to-life, matched cfDNA model that mirrors the complex genomic architecture of discordant twin pregnancies, we are empowering clinical laboratories to enhance assay sensitivity, ensure robust performance, and ultimately increase confidence in reproductive health screening results."

Key Features and Benefits:

• Clinically Relevant Discordance: Simulates a challenging twin pregnancy scenario featuring a Trisomy 21 female fetus combined with an unaffected male co-twin.
• Full-Process Control: Derived from human source materials to mimic patient cfDNA fragmentation patterns, suitable for end-to-end evaluation from extraction through NGS library preparation, sequencing, and bioinformatic analysis.
• Lyophilized Format: Ensured ambient stability and extended shelf-life for seamless global shipping and simplified laboratory storage.
• ISO 13485 Manufactured: Produced in cGMP-compliant, ISO 13485-certified facilities to guarantee high lot-to-lot consistency and reliable quality standards

The Seraseq® Discordant Twins - Matched cfDNA (T21 Female / Euploid Male) (Lyophilized) is available for order immediately under Material Number 0720-1188.
To learn more about LGC Clinical Diagnostics' comprehensive reproductive health quality solutions, visit www.seracare.com or contact customer service at [email protected]

About LGC Clinical Diagnostics
LGC Clinical Diagnostics, a business unit of LGC, is a leading provider of quality solutions for molecular diagnostics, clinical chemistry, immunoassay, and serology applications. Partnering with IVD manufacturers, clinical laboratories, CROs, and academic institutions worldwide, LGC Clinical Diagnostics offers a comprehensive portfolio of catalogue and custom reference materials, controls, and calibration solutions across infectious disease, oncology, inherited disease, and reproductive health testing. Its diagnostic quality solutions are developed and manufactured under cGMP and ISO 13485 standards across facilities in North America and Europe.

About SeraCare
Part of LGC Clinical Diagnostics, SeraCare develops and manufactures quality control materials and reference standards for clinical diagnostics. Its Seraseq&reg product line provides highly multiplexed, patient-like reference materials for Next-Generation Sequencing assays in clinical oncology, reproductive health (NIPT), and inherited disorders, supporting laboratory accuracy and assay validation worldwide.

Media Contact:
LGC Clinical Diagnostics
Email:[email protected]
Web:www.seracare.com